PS
Therapeutic Areas
Disc Medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bitopertin | Erythropoietic Protoporphyria (EPP) & X-Linked Protoporphyria (XLP) | Phase 3 |
| DISC-0974 | Anemia of Myelofibrosis (MF) | Phase 2 |
| DISC-0998 | Anemia Associated with Inflammatory Diseases | Preclinical |
| DISC-3405 | Polycythemia Vera | Phase 2 |
Leadership Team at Disc Medicine
JQ
John Quisel
Chief Executive Officer
JF
Jean Franchi
Chief Financial Officer
JY
Jonathan Yu
Chief Operating Officer
WS
Will Savage
Chief Medical Officer
SC
Steve Caffé
Chief Regulatory Officer
RR
Rahul Rajan Kaushik
Chief Technical Officer
RK
Rahul Khara
Chief Legal Officer
LA
Lisa Amaya Price
Chief Human Resources Officer
SV
Srikanth Venkatraman
SVP, Head of Chemistry
HY
Hua Yang
SVP, Head of Early Development and Clinical Pharmacology